Medication History versus Point-of-Care Platelet Activity Testing in Patients with Intracerebral Hemorrhage

Matthew B. Maas*, Andrew M. Naidech, Minjee Kim, Ayush Batra, Edward M. Manno, Farzaneh A. Sorond, Shyam Prabhakaran, Eric M. Liotta

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objective: We evaluated whether reduced platelet activity detected by point-of-care (POC) testing is a better predictor of hematoma expansion and poor functional outcomes in patients with intracerebral hemorrhage (ICH) than a history of antiplatelet medication exposure. Methods: Patients presenting with spontaneous ICH were enrolled in a prospective observational cohort study that collected demographic, clinical, laboratory, and radiographic data. We measured platelet activity using the PFA-100 (Siemens AG, Germany) and VerifyNow-ASA (Accumetrics, CA) systems on admission. We performed univariate and adjusted multivariate analyses to assess the strength of association between those measures and (1) hematoma growth at 24 hours and (2) functional outcomes measured by the modified Rankin Scale (mRS) at 3 months. Results: We identified 278 patients for analysis (mean age 65 ± 15, median ICH score 1 [interquartile range 0-2]), among whom 164 underwent initial neuroimaging within 6 hours of symptom onset. Univariate association with hematoma growth was stronger for antiplatelet medication history than POC measures, which was confirmed in multivariable models (β 3.64 [95% confidence interval [CI] 1.02-6.26], P =.007), with a larger effect size measured in the under 6-hour subgroup (β 7.20 [95% CI 3.35-11.1], P <.001). Moreover, antiplatelet medication history, but not POC measures of platelet activity, was independently associated with poor outcome at 3 months (mRS 4-6) in the under 6-hour subgroup (adjusted OR 3.6 [95% CI 1.2-11], P =.023). Conclusion: A history of antiplatelet medication use better identifies patients at risk for hematoma growth and poor functional outcomes than POC measures of platelet activity after spontaneous ICH.

Original languageEnglish (US)
Pages (from-to)1167-1173
Number of pages7
JournalJournal of Stroke and Cerebrovascular Diseases
Issue number5
StatePublished - May 2018


  • Intracerebral hemorrhage
  • antiplatelet
  • hemorrhagic stroke
  • hemostasis
  • intracranial hemorrhage
  • platelet dysfunction

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Rehabilitation
  • Surgery


Dive into the research topics of 'Medication History versus Point-of-Care Platelet Activity Testing in Patients with Intracerebral Hemorrhage'. Together they form a unique fingerprint.

Cite this